Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/38—Nitrogen atoms
  • C07D215/42—Nitrogen atoms attached in position 4
  • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
  • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Definitions

• the present invention relates to 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7- ethynyl-3-quinolinecarbonitriles and to methods for using them in the treatment of ischemic injury.
• Stroke is the third leading cause of death and the major cause of disability in the US, where approximately 750,000 strokes occur each year. Ischemic stroke comprises about 80% of this number, with primary intracerebral hemorrhagic stroke about 15- 20%.
• thrombolytic therapy by means of intravenous administration of t-PA, recombinant tissue plasminogen activator.
• the usefulness of this therapy is extremely limited. It must be given within a three hour window after the onset of symptoms, while a majority of patients seek and/or receive treatment after a substantial delay.
• treatment with t-PA carries an increased risk of causing intracerebral hemorrhage, a potentially devastating complication. Presence of hemorrhage must be ruled out prior to treatment and blood pressure must be carefully managed and monitored during and after treatment with t-PA.
• no neuroprotective therapy is available for treatment of ischemic stroke, hemorrhagic stroke or brain trauma. New treatments for stroke and other conditions associated with vascular permeability are greatly needed.
• R is methyl or ethyl
• R' and R" are independently alkyl of 1 to 3 carbon atoms, or R' and R", taken together with the nitrogen to which they are attached, can form a 5 or 6 membered saturated ring which may optionally contain an additional heteroatom selected from NR'", O or S(O) n ; n is 0-2; and R'" is hydrogen or alkyl of 1 to 3 carbon atoms; and pharmaceutically acceptable salts thereof.
• R' and R" taken together with the nitrogen to which they are attached, form a N-(C 1 -C 3 )-alkyl piperazine, piperidine, piperazine or morpholine.
• R is methyl
• R' and R" taken together with the nitrogen atom to which they are attached, form a N-(C 1 -C 3 )-alkyl piperazine, piperazine or morpholine ring.
• R' and R" taken together with the nitrogen to which they are attached form a N-(C r C 3 )-alkyl piperazine, preferably they form N-methylpiperazine.
• R' and R" are methyl.
• Pharmaceutically acceptable salts are those derived from organic and inorganic acids such as: acetic, lactic, carboxylic, citric, cinnamic, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, glycolic, pyruvic, methanesulfonic, ethanesulfonic, toluenesulfonic, salicylic, benzoic, and similarly known pharmaceutically acceptable acids.
• organic and inorganic acids such as: acetic, lactic, carboxylic, citric, cinnamic, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, glycolic, pyruvic, methanesulfonic, ethan
• Five or six membered saturated rings optionally containing one additional heteroatom selected from NR'", O or S(O) n as defined by N R'R" include, but are not limited to, pyrrolidine, pyrazolidine, imidazolidine, piperidine, piperazine, morpholine, thiomorpholine, 1-oxo-1-thiomorpholine and 1,1-dioxo-1 ⁇ thiomorpholine.
• compositions comprising the compounds described herein and at least one pharmaceutically acceptable carrier or excipient, and methods of treating ischemic injury using these compounds.
• the compounds of the invention are prepared as illustrated below.
• the compounds of this invention were prepared from: (a) commercially available starting materials (b) known starting materials which can be prepared as described in literature procedures or (c) new intermediates described in the schemes and experimental procedures herein.
• Reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformation being effected. It is understood by those skilled in the art of organic synthesis that the various functionalities present on the molecule must be consistent with the chemical transformations proposed. When not specified, order of synthetic steps, choice of protecting groups and deprotection conditions will be readily apparent to those skilled in the art. In addition, in some instances, substituents on the starting materials may be incompatible with certain reaction conditions. Restrictions pertinent to given substituents will be apparent to one skilled in the art. Reactions were run under inert atmospheres where appropriate.
• reaction of compounds of formula 1a-d with amines of formula 3 can be performed in a solvent system of triethylamine and N 1 N- dimethylformamide or alternatively in the presence of a base such as potassium carbonate in a solvent system of methanol and tetrahydrofuran.
• a base such as potassium carbonate in a solvent system of methanol and tetrahydrofuran.
• Recombinant human Src enzyme was obtained from PanVera (P3044). Biotinylated peptide corresponding to residues 6 - 20 of Cdk1 was used as a substrate (Biotin- KVEKIGEGTYGWYK-COOH). Homogeneous fluorescence resonance energy transfer kinase assays were performed using the europium/APC detection format (LANCE, Perkin Elmer). Src enzyme (10 ng) was mixed with biotinylated peptide (final concentration 2 ⁇ M), 50 mM Hepes (pH 7.5), 10 mM MgCI 2 , 20 ⁇ g/ml BSA, 0.001% Brij-35 (Sigma), 100 ⁇ M ATP, 1% DMSO.
• the kinase reaction was incubated for 70 min at 37°C.
• the reaction was stopped with EDTA at a final concentration of 3OmM EDTA/25mM Hepes (pH 7.5)/10 ⁇ g/ml BSA.
• the mixture was combined with Eu-labeled anti-phosphotyrosine antibody PT66 (Perkin Elmer, AD0068) and Streptavidin Surelight-APC (Perkin Elmer, CR130-100) in 50 mM Hepes (pH 7.5)/ 20 ⁇ g/ml BSA, and incubated for 30 min according to manufacturer's specifications. Fluorescence intensity at 665 nm was used to monitor the extent of the kinase reaction. Multiple entries for a given compound indicate that it was tested multiple times. The results obtained for representative compounds of this invention are listed in Table 1.
• Rat2 fibroblasts stably transformed with a plasmid containing a CMV promotor controlled v-Src/Hu c-Src fusion gene in which the catalytic domain of human c-Src was inserted in place of the v-Src catalytic domain in the v-Src gene are used for the measurement of src dependent suspension growth.
• Ultra-low cluster plates (Costar # 3474) are seeded with 10,000 cells per well on Day 1.
• Example 2 provides neuroprotection in a model of transient focal ischemia
• Example 2 was tested in a rat model of transient focal ischemia.
• Wistar rats were subjected to a 90 min occlusion of the middle cerebral artery (MCA) using an intraluminal suture approach as described by Longa et al., Stroke 1989, 20:84 followed by reperfusion for 48 hours.
• MCA middle cerebral artery
• animals received compound of Example 2 as a single i.v. bolus in 5% dextrose, 0.9% lactic acid at pH 4.5-5.0 (3 mg/kg, 10 mg/kg or 30 mg/kg).
• the animals were evaluated over a 48 hour period for neurological function deficit.
• Example 2 Infarct size was measured following sacrifice at 48 hours post MCA occlusion. 10 and 30 mg/kg doses of Example 2 significantly improved recovery from stroke-induced neurological deficits 35% and 53%, respectively as a percent of control (statistical error: 10-12%). Statistically significant reductions in the volume of infarcted brain tissue were observed at 10 mg/kg and 30 mg/kg of Example 2, showing a 32% and 40% reduction in infarct volume as a percent of control (statistical error; 7-10%). IV administration of Example 2 provides neuroprotection and improves long- term neurological recovery in a model of permanent focal ischemia
• Example 2 was tested in a rat model of permanent occlusion of middle cerebral artery, without the reperfusion, substantially as described by Chen et al., Stroke, 1986, 17:738. This is a more stringent model than the transient focal ischemia.
• Two hours following an electrocoagulation of middle cerebral artery, vehicle or Example 2 were administered at 10 mg/kg i.v followed by 3 additional doses of 10 mg/kg iv administered at 4, 24 and 26 hours post-induction of stroke.
• volume of infracted brain tissue was evaluated at 48 hour post-stroke.
• animals were subjected to testing of sensori-motor function based on tactile and propioceptive limb placement substantially as described by DeRyck et al., Brain Res.
• Example 2 significantly improved long-term sensorimotor recovery from neurological deficits induced in this stroke model.
• Example 2 provides neuroprotection in the model of hemorrhagic stroke
• Example 2 was tested in a rat model of intracerebral hemorrhage induced by intrastriatal infusion of collagenase substantially as described by Rosenberg et al., Stroke, 1990, 20:801. In this model, infusion of collagenase into caudate nucleus leads to proteolytic destruction of collagen in basal lamina of blood vessels and induces intracranial bleeding and edema peaking in 24-48 hours.
• Example 2 was administered at 4 hours post-induction of hemorrhagic stroke as a single i.v injection at the doses of 10 mg/kg or 30 mg/kg. 24 hours later brain water content was determined as a measure of edema. Results indicate that Example 2 significantly reduces post-hemorrhagic brain edema at both tested doses by 18% and 24% respectively.
• Vascular permeability due to disease, injury, or other trauma may occur in a variety of tissues and organs including organs of the central nervous system, cardiopulmonary system, gastrointestinal system and renal system.
• Compounds of the present invention are useful for inhibiting vascular permeability caused by disease, injury, or other trauma.
• vascular permeability may be inhibited in cerebral and spinal tissue following cerebrovascular events.
• Vascular permeability is a major cause of vascular leakage and/or edema following a cerebrovascular event and often leads to neurological disorders and disabilities. Cerebrovascular events including, but not limited to transient and acute ischemic events, may be treated in accordance with the present invention.
• Acute events include, but are not limited to, stroke, head trauma, spinal trauma, general anoxia, hypoxia including fetal hypoxia, hypoglycemia, hypotension as well as similar injuries seen during procedures from embole, hyperfusion and hypoxia.
• Stroke includes, but is not limited to focal and global ischemia, transient cerebral ischemic attacks, and other cerebral vascular problems accompanied by cerebral ischemia.
• the instant invention would also be useful for a range of cerebrovascular events including cerebral hemmorhage, infarction due to embolism or thrombosis of the intra- or extra cranial arteries, perinatal asphyxia, in cardiac arrest and status epilepticus, especially where blood flow to the brain is halted for a period of time.
• Cerebrovascular events associated with vascular leakage also include infections, including, but not limited to encephalitis and meningitis associated with neuroinflammation, which, through vascular leakage propagate injury to surrounding tissues.
• Systemic disease such as diabetes, multiple sclerosis, kidney disease and atherosclerosis may also result in increased vascular permeability.
• Compounds of the present invention are also useful for inhibiting vascular permeability triggered by local tissue/organ ischemic (hypoxic) event outside of the central nervous system, including, but not limited to myocardial ischemia and ischemic bowel disease.
• Compounds of the present invention provide neuroprotection in a patient.
• Neuroprotection refers to the protection of neural cells against cell death or apoptosis.
• One measure of the extent of cell death or apoptosis is infarct volume; the volume of necrotic or dead brain tissue. Imaging techniques and the patient's clinical status can be used to assess infarct volume following an ischemic event.
• Compounds of the present invention reduce infarct volume of a patient as compared to typical infarct volume experienced in similar ischemic events in the absence of agents of the present invention.
• Compounds of the present invention prevent, reduce or inhibit neurodegeneration and/or neurotoxicity associated with vascular permeability that result in symptoms including, but not limited to, visual impairment such as sudden vision loss or diplopia, speech or language impairment such as aphasia or dysarthia, memory impairment, cognitive impairment or dysfunction ranging from mild cognitive impairment to dementia, and motor impairment including, but not limited to, parathesia, loss of muscle control, weakness, numbness or paralysis. Neurological deficits such as those described above, resulting from injury or disease described above may be inhibited or prevented in accordance with the present invention.
• the present invention provides methods of treating, preventing, inhibiting or alleviating conditions associated with vascular leakage or permeability listed above in a mammal, preferably in a human, the methods comprising providing a pharmaceutically effective amount, and in particular a vascular permeability inhibiting amount, of a compound of this invention to the mammal, and in particular a human patient, in need thereof.
• compositions for treating or modulating vascular permeability comprising at least one compound of Formula I, mixtures thereof, and or pharmaceutical salts thereof, and a pharmaceutically acceptable carrier therefore.
• Such compositions are prepared in accordance with acceptable pharmaceutical procedures, such as described in Remingtons Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985).
• Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable.
• Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs including intravenous solutions.
• the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, organic solvent, or a mixture of both.
• the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, osmo-regulators, antioxidants and antifoaming agents.
• liquid carriers for oral, intravenous and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), saline, dextrose solutions, dextrose-saline and dextrose-water solutions, alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives.
• Liquid carriers are used in sterile form for parenteral and intravenous administration. PH of liquid formulations may be adjusted in some cases by the addition of HCI, sodium hydroxide, and phosphoric acid.
• compositions of the present invention are liquid pharmaceutical compositions which are sterile solutions or suspensions in an iso-osmotic, physiologically compatible buffered system.
• Liquid pharmaceutical compositions of the present invention can be administered by, for example, intramuscular, intraperitoneal, intravenous, or subcutaneous injection.
• Pharmaceutical compositions of the present invention are preferably administered to a patient by intraperitoneal or intravenous injection. Most preferably, the composition is administered intravenously such as by intravenous bolus injection, intravenous i.v. drip, repeated slow bolus administration or infusion.
• Oral administration may be either liquid or solid composition form.
• the compounds of this invention may also be administered orally or parentally, neat or in combination with conventional pharmaceutical carriers.
• Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material.
• the carrier is a finely divided solid, which is in admixture with the finely divided active ingredient.
• the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
• the powders and tablets preferably contain up to 99% of the active ingredient.
• Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
• the pharmaceutical composition is in unit dosage form, e.g. as tablets, capsules, powders, solutions, suspensions, emulsions, granules, suppositories, ampule, or bolus.
• the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
• the unit dosage forms can be packaged compositions, for example packeted powders, lyophilyzed powder or cake in ampoules or vials, or vials, ampoules, prefilled syringes or sachets containing liquids.
• the unit dosage form can be, for example, capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
• the dose provided to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, and the state of the patient, the manner of administration, and the like.
• a "therapeutically effective amount” is an amount sufficient to cure or ameliorate symptoms of a disease or injury.
• a single dose (or dosage form) will contain from about 1 mg/kg to about 30 mg/kg, and more preferably from about 1 mg/kg to about 10 mg/kg of compound of the present invention. It is expected that some patients will receive multiple doses.
• the dosage to be used in the treatment of a specific case must be subjectively determined by the attending physician. The variables involved include the specific condition and the size, age and response pattern of the patient.
• the present invention provides advantages over previously known treatments for stroke and other conditions associated with vascular permeability.
• compounds of the present invention may be effective in preventing neurodegeneration and development of neurological deficits in some patients when administered 6-18 hours after injury and even up to about 18-24 hours after ischemic injury.
• treatment may continue and improvement in a patient's prognosis may result from continuous or repeated administration of compound of the present invention for up to about 72 hours or longer following ischemic injury.
• Provide as used herein means either directly administering a compound or composition of the present invention, or administering a prodrug, derivative or analog which will form an equivalent amount of the active compound or substance within the body.
• the present invention includes prodrugs of compounds of Formula I.
• Prodrug as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of Formula I.
• Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed).
• Example 2 The same procedure used for the synthesis of Example 1 is followed to provide 90 mg (25%) of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[4-(4-methyl- piperazin-1-yl)but-1-ynyl]-3-quinolinecarbonitrile as a yellow solid, mp 165-167 0 C; 1 H NMR (DMSO-d 6 ) ⁇ 2.17 (s, 3H), 2.35 (bs, 4H), 2.50 (bs, 4H), 2.60-2.68 (m, 4H), 3.86 (s, 3H), 3.96 (s, 3H), 7.34 (s, 1 H), 7.74 (s, 1 H), 7.83 (s, 1 H), 7.88 (s, 1H), 8.43 (s, 1H) 1 9.83 (bs, 1 H) 1 MS (ES) m/z 524.2 (M+H)+. Analysis for C 27 H 27 CI 2 N 5 O 2 - 1.5 H2O
• Example 2 Alternative Preparation of Example 2: A mixture of 3-cyano-4-[(2,4-dichloro-5-methoxyphenyl)anilino]-6-methoxy-7- quinolinyl trifluoromethanesulfonate (2.5 g, 4.8 mmol), 1-but-3-ynyl-4-methyl- piperazine (1.8 g, 11.8 mmol) [Vaillancourt, V. A. et. al.
• WO2002002558A1 bis(triphenylphosphine)palladium dichloride (170 mg, 0.22 mmol), potassium carbonate (3.31 g, 0.024 mol), triphenylphosphine (25 mg, 0.9 mmol) and copper iodide (45 mg, 0.22 mmol) in a mixture of 6 ml_ of methanol and 30 ml_ of tetrahydrofuran is heated at 60 0 C for 4 hours and then cooled to room temperature. Ethyl acetate and water are added. The organic layer is extracted, dried over magnesium sulfate, filtered and concentrated.
• WO2002002558A1 bis(triphenylphosphine)palladium dichloride (14 mg, 0.02 mmol), triphenylphosphine (21 mg, 0.08 mmol) and copper iodide (5 mg, 0.02 mmol) in a mixture of 2 ml_ of triethylamine and 1 ml_ of N-methyl- pyrrolidinone is heated at 70 0 C for 4 hours and then cooled to room temperature. Ethyl acetate and water are added. The organic layer is extracted, dried over magnesium sulfate, filtered and concentrated.
• Example 1 The same procedure used for the synthesis of Example 1 is followed to provide 150 mg (43%) of 4-[(2,4-dichIoro-5-methoxyphenyl)amino]-6-methoxy-7-(4-morpholin-4- ylbut-1-ynyl)-3-quinolinecarbonitrile as a yellow solid, mp 140-142 0 C; 1 H NMR

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Hospice & Palliative Care (AREA)
• Vascular Medicine (AREA)
• Psychiatry (AREA)
• Urology & Nephrology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Quinoline Compounds (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=35784691

Family Applications (1)

Country Status (23)

Cited By (1)

Families Citing this family (3)

Citations (2)

Family Cites Families (3)

• 2005
  • 2005-10-21 RU RU2007111704/04A patent/RU2007111704A/ru not_active Application Discontinuation
  • 2005-10-21 AT AT05820982T patent/ATE391122T1/de not_active IP Right Cessation
  • 2005-10-21 KR KR1020077011472A patent/KR20070085413A/ko not_active Withdrawn
  • 2005-10-21 BR BRPI0516995-0A patent/BRPI0516995A/pt not_active IP Right Cessation
  • 2005-10-21 US US11/255,556 patent/US20060116375A1/en not_active Abandoned
  • 2005-10-21 DE DE602005005843T patent/DE602005005843T2/de not_active Expired - Lifetime
  • 2005-10-21 SI SI200530255T patent/SI1802581T1/sl unknown
  • 2005-10-21 PL PL05820982T patent/PL1802581T3/pl unknown
  • 2005-10-21 MX MX2007004833A patent/MX2007004833A/es active IP Right Grant
  • 2005-10-21 JP JP2007538054A patent/JP2008517924A/ja not_active Withdrawn
  • 2005-10-21 PT PT05820982T patent/PT1802581E/pt unknown
  • 2005-10-21 CA CA002581807A patent/CA2581807A1/en not_active Abandoned
  • 2005-10-21 WO PCT/US2005/037839 patent/WO2006047262A1/en not_active Ceased
  • 2005-10-21 EP EP05820982A patent/EP1802581B1/en not_active Expired - Lifetime
  • 2005-10-21 AU AU2005299822A patent/AU2005299822A1/en not_active Abandoned
  • 2005-10-21 CN CNA2005800360383A patent/CN101044117A/zh active Pending
  • 2005-10-21 ES ES05820982T patent/ES2303287T3/es not_active Expired - Lifetime
  • 2005-10-21 DK DK05820982T patent/DK1802581T3/da active
• 2007
  • 2007-03-30 NO NO20071708A patent/NO20071708L/no not_active Application Discontinuation
  • 2007-04-11 EC EC2007007385A patent/ECSP077385A/es unknown
  • 2007-04-12 IL IL182547A patent/IL182547A0/en unknown
  • 2007-04-20 CR CR9072A patent/CR9072A/es not_active Application Discontinuation
  • 2007-04-20 ZA ZA200703275A patent/ZA200703275B/xx unknown

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events